Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.40K | -- | -- | 35.80K | 71.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.40K | -- | -- | 35.80K | 71.60K |
| Cost of Revenue | 5.70K | -- | -- | 71.70K | 53.30K |
| Gross Profit | 10.70K | -- | -- | -35.90K | 18.40K |
| SG&A Expenses | 52.90K | 100.20K | 119.30K | 248.10K | 183.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.30K | 222.40K | 167.40K | 366.70K | 281.40K |
| Operating Income | -167.80K | -222.40K | -167.40K | -330.90K | -209.80K |
| Income Before Tax | -200.10K | -252.00K | -195.90K | -980.20K | -231.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -200.10K | -252.00K | -195.90K | -980.20K | -231.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.10K | -252.00K | -195.90K | -980.20K | -231.10K |
| EBIT | -167.80K | -222.40K | -167.40K | -330.90K | -209.80K |
| EBITDA | -167.00K | -163.60K | -107.70K | -271.80K | -149.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Average Diluted Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
